Last updated on 4/28/26 | First published on 5/20/24 | Literature review current through Mar. 2026
[cite]
INTRODUCTION
Long COVID is estimated to affect 25–50 million individuals in the United States and up to one billion worldwide. To date, no universally accepted, effective therapy exists to address the full spectrum of Long COVID symptoms. Emerging clinical evidence suggests that hyperbaric oxygen therapy (HBOT) may be an effective and well-tolerated adjunctive treatment option.
In this recorded webinar, Dr. D. Craig Lindsey provides an update on the use of HBOT for Long COVID, with insights spanning both clinical outcomes and reimbursement considerations.
For an evidence-based overview on the use of HBOT for Long COVID, including epidemiology, risk factors, etiology, pathophysiology, history, diagnosis, current treatment alternatives, and current evidence on the use of HBOT for Long COVID, see topic "HBO Treatment Emerging Indication: Long COVID" and blog post "Beyond Clinical Evidence: Navigating the Barriers to HBOT in Long COVID Treatment".
Target audience:
- Care settings: hyperbaric oxygen therapy programs
HYPERBARIC OXYGEN TREATMENT OF LONG COVID
RELATED TOPICS
Official reprint from WoundReference® woundreference.com ©2026 Wound Reference, Inc. All Rights Reserved
Use of WoundReference is subject to the
Subscription and License Agreement.
NOTE: This is a controlled document. This document is not a substitute for proper training, experience, and exercising of professional judgment. While every effort has been made to ensure the accuracy of the contents, neither the authors nor the Wound Reference, Inc. give any guarantee as to the accuracy of the information contained in them nor accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omissions in the contents of the work.
